Share-based Payment Arrangement, Expense of Aldeyra Therapeutics, Inc. from 31 Mar 2013 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aldeyra Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2013 to 31 Dec 2025.
  • Aldeyra Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $1,090,083, a 14% decline year-over-year.
  • Aldeyra Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $6,091,413, a 24% decline year-over-year.
  • Aldeyra Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $6,091,413, a 24% decline from 2024.
  • Aldeyra Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $7,973,499, a 39% increase from 2023.
  • Aldeyra Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5,752,771, a 31% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Aldeyra Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $6,091,413 $1,090,083 -$173,256 -14% 01 Oct 2025 31 Dec 2025 10-K 27 Feb 2026 2025 FY
Q3 2025 $6,264,669 $2,580,753 -$645,041 -20% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $6,909,710 $196,564 -$1,738,965 -90% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $8,648,675 $2,224,013 +$675,176 +44% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $7,973,499 $1,263,339 +$2,063,681 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2026 2025 FY
Q3 2024 $5,909,818 $3,225,794 +$2,436,577 +309% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $3,473,241 $1,935,529 +$361,989 +23% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $3,111,252 $1,548,837 -$2,641,519 -63% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $5,752,771 $800,342 -$3,621,634 -128% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q3 2023 $9,374,405 $789,217 -$1,447,554 -65% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $10,821,959 $1,573,540 +$279,205 +22% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $10,542,754 $4,190,356 +$2,253,778 +116% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $8,288,976 $2,821,292 +$1,836,818 +187% 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
Q3 2022 $6,452,158 $2,236,771 +$818,435 +58% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $5,633,723 $1,294,335 -$1,029,226 -44% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $6,662,949 $1,936,578 -$445,078 -19% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $7,108,027 $984,474 -$645,816 -40% 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $7,753,843 $1,418,336 -$339,143 -19% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $8,092,986 $2,323,561 +$581,172 +33% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022 2022 Q2
Q1 2021 $7,511,814 $2,381,656 +$428,004 +22% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $7,083,810 $1,630,290 -$318,472 -16% 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
Q3 2020 $7,402,282 $1,757,479 -$395,459 -18% 01 Jul 2020 30 Sep 2020 10-Q 28 Oct 2021 2021 Q3
Q2 2020 $7,797,741 $1,742,389 -$352,573 -17% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $8,150,314 $1,953,652 +$67,563 +3.6% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $8,082,751 $1,948,762 +$930,828 +91% 01 Oct 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
Q3 2019 $7,151,923 $2,152,938 +$879,218 +69% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $6,272,705 $2,094,962 +$1,110,178 +113% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $5,162,527 $1,886,089 +$1,017,674 +117% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $4,144,853 $1,017,934 +$425,761 +72% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $3,719,092 $1,273,720 +$614,381 +93% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $3,104,711 $984,784 +$379,551 +63% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2019 Q2
Q1 2018 $2,725,160 $868,415 +$10,319 +1.2% 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q4 2017 $2,714,841 $592,173 -$7,866 -1.3% 01 Oct 2017 31 Dec 2017 10-K 08 Mar 2019 2018 FY
Q3 2017 $2,722,707 $659,339 -$217,686 -25% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3
Q2 2017 $2,940,393 $605,233 -$68,348 -10% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $3,008,741 $858,096 +$248,988 +41% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2017 2017 Q1
Q4 2016 $2,759,753 $600,039 +$52,867 +9.7% 01 Oct 2016 31 Dec 2016 10-K 30 Mar 2017 2016 FY
Q3 2016 $2,706,886 $877,025 +$340,756 +64% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $2,366,130 $673,581 +$209,993 +45% 01 Apr 2016 30 Jun 2016 10-Q 07 Aug 2017 2017 Q2
Q1 2016 $2,156,137 $609,108 -$30,965 -4.8% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017 2017 Q1
Q4 2015 $2,187,102 $547,172 +$81,996 +18% 01 Oct 2015 31 Dec 2015 10-K 30 Mar 2017 2016 FY
Q3 2015 $2,105,106 $536,269 +$78,480 +17% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016 2016 Q3
Q2 2015 $2,026,626 $463,588 -$284,834 -38% 01 Apr 2015 30 Jun 2015 10-Q 10 Aug 2016 2016 Q2
Q1 2015 $2,311,460 $640,073 +$274,387 +75% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016 2016 Q1
Q4 2014 $2,037,073 $465,176 +$91,938 +25% 01 Oct 2014 31 Dec 2014 10-K 30 Mar 2016 2015 FY
Q3 2014 $1,945,135 $457,789 -$195,862 -30% 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2015 2015 Q3
Q2 2014 $2,140,997 $748,422 +$124,045 +20% 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015 2015 Q2
Q1 2014 $2,016,952 $365,686 +$315,239 +625% 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q1
Q4 2013 $1,701,713 $373,238 01 Oct 2013 31 Dec 2013 10-K 23 Mar 2015 2014 FY
Q3 2013 $653,651 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014 2014 Q3
Q2 2013 $624,377 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2
Q1 2013 $50,447 01 Jan 2013 31 Mar 2013 10-Q 11 Jun 2014 2014 Q1

Aldeyra Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $6,091,413 -$1,882,086 -24% 01 Jan 2025 31 Dec 2025 10-K 27 Feb 2026 2025 FY
2024 $7,973,499 +$2,220,728 +39% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2026 2025 FY
2023 $5,752,771 -$2,536,205 -31% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
2022 $8,288,976 +$1,180,949 +17% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2021 $7,108,027 +$24,217 +0.34% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $7,083,810 -$998,941 -12% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
2019 $8,082,751 +$3,937,898 +95% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
2018 $4,144,853 +$1,430,012 +53% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
2017 $2,714,841 -$44,912 -1.6% 01 Jan 2017 31 Dec 2017 10-K 08 Mar 2019 2018 FY
2016 $2,759,753 +$572,651 +26% 01 Jan 2016 31 Dec 2016 10-K 30 Mar 2017 2016 FY
2015 $2,187,102 +$150,029 +7.4% 01 Jan 2015 31 Dec 2015 10-K 30 Mar 2017 2016 FY
2014 $2,037,073 +$335,360 +20% 01 Jan 2014 31 Dec 2014 10-K 30 Mar 2016 2015 FY
2013 $1,701,713 01 Jan 2013 31 Dec 2013 10-K 23 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.